Financial Contrast: Lipocine (LPCN) & Its Peers
Lipocine (NASDAQ: LPCN) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Lipocine to related businesses based on the strength of its risk, earnings, dividends, institutional ownership, analyst recommendations, profitability and valuation.
Institutional & Insider Ownership
26.2% of Lipocine shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 11.3% of Lipocine shares are held by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Lipocine and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Lipocine currently has a consensus target price of $24.67, indicating a potential upside of 598.77%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.69%. Given Lipocine’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Lipocine is more favorable than its rivals.
This table compares Lipocine and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Lipocine has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Lipocine’s rivals have a beta of 6.62, suggesting that their average stock price is 562% more volatile than the S&P 500.
Earnings & Valuation
This table compares Lipocine and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Lipocine Competitors||$260.16 million||$66.28 million||-6.36|
Lipocine’s rivals have higher revenue and earnings than Lipocine. Lipocine is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Lipocine rivals beat Lipocine on 7 of the 12 factors compared.
Lipocine Company Profile
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.